1. Home
  2. /
  3. PHUSE Open Source Technology

Open Source Technology

Welcome to PHUSE’s recently launched Open Source Technology area! Please note, this website section is currently in development and the full launch will be coming soon. In the meantime, enjoy the overview of the content below and reach out to Michael Rimler: michael.rimler@phuse.global, PHUSE Open Source Technologies Director, if you would like to learn more.

Visit the PHUSE Education portal for even more discussion on programming languages, technology and regulatory submissions, including connections to open-source technologies.

What is Open Source?

According to Merriam-Webster, open source is “having the source code freely available for possible modification and redistribution”. Wikipedia defines open-source software (OSS) as a computer software as computer software that is released under a licence in which the copyright holder grants users the rights to use, study, change and distribute the software and its source code to anyone and for any purpose.

The use of open-source technology is not new to life sciences, but interest in its application within clinical data analytics has significantly increased in recent years. Interest has been mostly focused on R programming for pharmaceutical and vaccine clinical reporting, through there has been some interest in other languages such as Python and Julia.

This page aims to provide a set of resources to support the PHUSE Community’s understanding of how open-source technology is impacting the future of life sciences and provide an entry point for getting involved.

Screenshot 2021-02-03 at 12.12.30.png

pharmaverse

pharmaverse logo.jpg

A connected network of companies and individuals working to promote collaborative development of curated open-source R packages for clinical reporting usage in pharma, in a space where previously we would have only ever worked in silos on our own closed-source and often duplicative solutions. Adopting shared solutions in this post-competitive space should ultimately ease regulatory review, resulting in bringing new treatments to patients faster.

Find Out More: https://pharmaverse.org/